Frequency of circulating tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially treg-depleting agents

Clinical Cancer Research

Volumn 17, Issue 4, 2011, Pages 841-848

  De Vries, I Jolanda M ^a   Castelli, Chiara ^b   Huygens, Caroline ^c   Jacobs, Joannes F M ^a   Stockis, Julie ^c   Schuler Thurner, Beatrice ^d   Adema, Gosse J ^a   Punt, Cornelis J A ^a   Rivoltini, Licia ^b   Schuler, Gerold ^d   Coulie, Pierre G ^c   Lucas, Sophie ^c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c DE DUVE INSTITUTE   (Belgium)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DACLIZUMAB; DENILEUKIN DIFTITOX; TRANSCRIPTION FACTOR FOXP3; TUMOR VACCINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DEMETHYLATION; FEMALE; HUMAN; HUMAN CELL; INTRON; LOW DRUG DOSE; MALE; MELANOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REGULATORY T LYMPHOCYTE; VACCINATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CELL COUNT; CYCLOPHOSPHAMIDE; DIPHTHERIA TOXIN; DNA METHYLATION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENETIC MARKERS; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-2; INTRONS; LYMPHOCYTE DEPLETION; MALE; MELANOMA; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; T-LYMPHOCYTES, REGULATORY;

EID: 79951831706     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2227     Document Type: Article

References (33)

1. Boon T, Coulie PG, Van Den Eynde B, Van Der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006;24:175-208.
2. Lesterhuis WJ, Aarntzen EH, De Vries IJ, et al. Dendritic cell vaccines in melanoma: from promise to proof?. Crit Rev Oncol Hematol 2008;66:118-34.
3. Connerotte T, Van Pel A, Godelaine D, et al. Functions of anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Res 2008;68:3931-40.
4. Germeau C, Ma W, Schiavetti F, et al. High frequency of anti-tumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 2005;201:241-8. (Pubitemid 40189433)
5. Lurquin C, Lethé B, Corbière V, et al. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 2005;201:249-57. (Pubitemid 40189434)
6. Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010;140:845-58.
7. Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol 2006; 24:209-26.
8. Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 2007;7:880-7. (Pubitemid 350006256)
9. Francois V, Ottaviani S, Renkvist N, et al. The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Res 2009;69:4335-45.
10. Gavin MA, Torgerson TR, Houston E, et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci U S A 2006; 103:6659-64.
11. Stockis J, Fink W, Francois V, et al. Comparison of stable human Treg and Th clones by transcriptional profiling. Eur J Immunol 2009;39:869-82.
12. Baron U, Floess S, Wieczorek G, et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol 2007;37:2378-89. (Pubitemid 47423608)
13. Floess S, Freyer J, Siewert C, et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 2007;5:e38.
14. Wieczorek G, Asemissen A, Model F, et al. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res 2009;69:599-608.
15. Zheng Y, Josefowicz S, Chaudhry A, Peng XP, Forbush K, Rudensky AY. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 2010;463:808-12.
16. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004;34:336-44. (Pubitemid 39255944)
17. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 1982;155:1063-74. (Pubitemid 12142723)
18. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 2005;28:582-92. (Pubitemid 41533092)
19. Audia S, Nicolas A, Cathelin D, et al. Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25 +T lymphocytes. Clin Exp Immunol 2007;150:523-30. (Pubitemid 350098743)
20. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623-33. (Pubitemid 43121851)
21. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641-8. (Pubitemid 46348738)
22. Mahnke K, Schonfeld K, Fondel S, et al. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 2007;120:2723-33. (Pubitemid 46651297)
23. Morse MA, Hobeika AC, Osada T, et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008;112:610-8.
24. Rasku MA, Clem AL, Telang S, et al. Transient T cell depletion causes regression of melanoma metastases. J Transl Med 2008;6:12;1-18.
25. Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 2009;1174:99-106.
26. Jacobs JFM, Punt CJA, Lesterhuis WJ, Sutmuller RP, Brouwer HM, Scharenborg NM, et al. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment, a phase I/II study in metastatic melanoma patients. Clin Cancer Res 2010;16:5067-78.
27. de Vries IJ, Lesterhuis WJ, Scharenborg NM, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003;9:5091-100. (Pubitemid 37413557)
28. Schuler-Thurner B, Schultz ES, Berger TG, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002;195:1279-88. (Pubitemid 34564330)
29. Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007;110:2983-90. (Pubitemid 350006952)
30. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3 +regulatory T cells in cancer patients. Blood 2006;107:2409-14. (Pubitemid 43345561)
31. Cesana GC, DeRaffele G, Cohen S, et al. Characterization of CD4+CD25 +regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006;24:1169-77. (Pubitemid 46638815)
32. Wei S, Kryczek I, Edwards RP, et al. Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res 2007;67:7487-94. (Pubitemid 47206578)
33. Zhang H, Chua KS, Guimond M, et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med 2005;11:1238-43. (Pubitemid 43093672)